8-K: Bausch + Lomb Reports Strong Q2 2024 Results, Raises Full-Year Guidance

Bausch + Lomb announced a 17% revenue increase in Q2 2024, driven by growth across all business segments, and raised its full-year revenue and adjusted EBITDA guidance.

Summary

• Bausch + Lomb reported a revenue of $1.216 billion for the second quarter of 2024, a 17% increase compared to $1.035 billion in the same period last year.
• On a constant currency basis, revenue grew by 20% year-over-year.
• The company experienced growth across all business segments: Vision Care revenue increased by 8% (11% constant currency), Surgical revenue increased by 7% (9% constant currency), and Pharmaceuticals revenue increased by 60% (61% constant currency).
• The net loss attributable to Bausch + Lomb was $151 million, compared to a $32 million loss in Q2 2023, primarily due to increased income taxes and interest expenses.
• Adjusted EBITDA for the quarter was $209 million, up from $179 million in Q2 2023.
• Cash flow from operations improved to $15 million, compared to a $24 million use of cash in the prior year's quarter.
• The company raised its full-year 2024 revenue guidance to $4.7 $4.8 billion and adjusted EBITDA guidance to $850 $900 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and raised guidance, but the increased net loss and decreased adjusted net income temper the overall sentiment.

Positives

• The company achieved robust revenue growth across all segments and geographies.
• The dry eye category saw strengthened leadership with growth in both prescription and over-the-counter products.
• The launch of innovative new products contributed to the positive results.
• Cash flow from operations improved significantly year-over-year.
• The company raised its full-year revenue and adjusted EBITDA guidance, indicating strong confidence in future performance.

Negatives

• The net loss attributable to Bausch + Lomb increased to $151 million, compared to a $32 million loss in the same quarter last year.
• Operating income decreased by $17 million due to higher selling, advertising, and promotion costs, as well as increased amortization expenses.
• Adjusted net income decreased to $45 million, compared to $65 million in the same quarter last year.
• GAAP Earnings Per Share (EPS) Basic and Diluted was ($0.43), compared to ($0.09) for the second quarter of 2023.
• Adjusted EPS was $0.13, compared to $0.18 for the second quarter of 2023.

Risks

• The company's performance is subject to risks and uncertainties, including those related to the spin-off from Bausch Health Companies Inc.
• The company faces risks related to the acquisition of XIIDRA and other ophthalmology assets, including potential failure to realize expected benefits and increased debt levels.
• Adverse economic conditions, including inflation and potential recession, could negatively impact revenue and margins.
• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Bausch + Lomb raised its full-year 2024 revenue guidance to $4.7 $4.8 billion, representing a 16-18% constant currency growth, and adjusted EBITDA guidance to $850 $900 million. The increase is due to strong Q2 performance and increased MIEBO revenue expectations, partially offset by a change in expected XIIDRA revenues.

Management Comments

• Our continued growth is being fueled by a relentless focus on selling and operational excellence, and a commitment to innovation that defined our past and will dictate our future, said Brent Saunders, chairman and CEO, Bausch + Lomb.
• That commitment was on full display in the second quarter, with the approval or launch of three innovative products across three distinct businesses, announced over 12 days.

Industry Context

The results reflect a positive trend in the eye health industry, with Bausch + Lomb demonstrating strong growth in key segments. The company's focus on innovation and strategic acquisitions, such as XIIDRA, positions it well within the competitive landscape.

Comparison to Industry Standards

• Bausch + Lomb's 20% constant currency revenue growth in Q2 2024 is strong compared to industry peers, such as Alcon, which reported a 10% constant currency growth in their most recent quarter.
• The 61% constant currency growth in the Pharmaceuticals segment, driven by the XIIDRA acquisition and MIEBO launch, significantly outperforms the average growth rate in the pharmaceutical sector.
• While Bausch + Lomb's net loss is a concern, the adjusted EBITDA growth of 17% indicates strong underlying operational performance, which is in line with or better than some competitors in the medical device and pharmaceutical space.
• The company's focus on new product launches, such as BLINK NutriTears, INFUSE for Astigmatism, and enVista Envy, demonstrates a commitment to innovation that is crucial for maintaining a competitive edge in the eye health market, similar to companies like Johnson & Johnson Vision.

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue and raised guidance, but may be concerned about the increased net loss.
• Employees may be encouraged by the company's growth and positive outlook.
• Customers will benefit from the launch of new and innovative products.
• Suppliers may see increased demand due to the company's growth.
• Creditors may view the improved cash flow from operations positively.

Next Steps

• The company will continue to focus on selling and operational excellence.
• Bausch + Lomb will continue to invest in innovation and new product launches.
• The company will monitor the performance of key products like MIEBO and XIIDRA.
• The company will host a conference call to discuss the results on July 31, 2024.

Key Dates

Keywords

Bausch + Lomb, eye health, financial results, revenue growth, adjusted EBITDA, pharmaceuticals, vision care, surgical, MIEBO, XIIDRA, constant currency, guidance